Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Operating Leases (2019 - 2025)

Syndax Pharmaceuticals (SNDX) has 7 years of Operating Leases data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 26.79% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 26.79%, while the annual FY2025 figure was $1.5 million, 26.79% down from the prior year.
  • Operating Leases reached $1.5 million in Q4 2025 per SNDX's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $2.0 million in Q4 2024 and bottomed at $22000.0 in Q2 2021.
  • Average Operating Leases over 5 years is $713875.0, with a median of $676000.0 recorded in 2022.
  • Peak YoY movement for Operating Leases: crashed 90.83% in 2021, then skyrocketed 2490.91% in 2022.
  • A 5-year view of Operating Leases shows it stood at $711000.0 in 2021, then fell by 0.28% to $709000.0 in 2022, then fell by 18.48% to $578000.0 in 2023, then skyrocketed by 254.5% to $2.0 million in 2024, then decreased by 26.79% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.5 million in Q4 2025, $2.0 million in Q4 2024, and $133000.0 in Q2 2024.